retatrutide health benefits 🚨 JUST RELEASED TODAY!!!! NEW PHASE 3 DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what is already one of the most interesting obesity drug The future of metabolic science

Key Takeaways 3 DailyMed-approved sites: Abdomen, front or outer thigh, and upper arm (DailyMed RETATRUTIDE PEN label) Self-injection: Abdomen and thigh are suitable for self-administration

During this process they discovered that crude secretin separated into two fractions

Central nervous system effects: GLP-1 receptors are present in the brain, and their activation is hypothesised to influence neurological pathways associated with energy levels and alertness, though this mechanism has not been fully established in humans

Like the injection, they'll be prescription-only once available in the UK

The back of the upper arm is the hardest site to self-administer

Although GLP-1R agonists exhibit protective and regulatory effects on blood glucose levels, they have been positively correlated with tumor progression in patients with diabetes [51, 73]